Skip to main content
main-content

Connective tissue diseases

Highlights

14-05-2020 | Pregnancy | Case study | Article

My lupus patient wants to get pregnant: What next?

Ana Rita Cruz-Machado and Laura Andreoli present a case study of a female patient with systemic lupus erythematosus on treatment with teratogenic immunosuppressive drugs who wanted to have a child.

07-04-2020 | Systemic lupus erythematosus | Feature | Article

In pursuit of new lupus therapies: The importance of trial endpoints

Eric Morand explores the reasons why the TULIP-1 and TULIP-2 trials of anifrolumab found different primary results, and discusses the search for optimal endpoints in lupus trials.

03-04-2020 | COVID-19 | Highlight | News

Rheumatologists urge caution on chloroquine, hydroxychloroquine use for COVID-19

Rheumatologists highlight that more research needs to be carried out before chloroquine and hydroxychloroquine can be recommended for the treatment of COVID-19, and emphasize the need for adequate supplies of these agents for people with rheumatic diseases.

26-02-2020 | Glucocorticoids | Highlight | News

Metformin could mitigate glucocorticoid-related complications

Findings from a proof-of-concept phase 2 study suggest that treatment with the antidiabetes drug metformin could help minimize some metabolic complications and improve clinical outcomes for patients taking systemic glucocorticoid therapy.

04-02-2020 | Cardiovascular disease | Highlight | News

Multidisciplinary approach needed for rheumatology patients with coronary artery disease

An analysis of percutaneous coronary intervention outcomes among people with rheumatic diseases suggests that those with systemic sclerosis have an elevated risk for multiple in-hospital complications, while patients with systemic lupus erythematosus have an increased bleeding risk.

15-01-2020 | Myositis | Editorial | Article

Do myositis-specific antibodies have an impact on the treatment of idiopathic inflammatory myopathies?

Latika Gupta and Rohit Aggarwal evaluate the use of myositis-specific antibodies in the classification and management of this disease.

17-12-2019 | Systemic lupus erythematosus | Highlight | News

Cumulative genetic risk score predicts SLE outcomes

People with a high genetic risk score for systemic lupus erythematosus experience earlier disease onset, as well as higher rates of complications and mortality, than those with a low score, researchers report.

07-10-2019 | Systemic lupus erythematosus | Highlight | News

Elevated IFN-α linked to relapse risk in SLE

A quarter of patients in remission for systemic lupus erythematosus have elevated serum interferon-α levels and may be at increased risk for relapse, French researchers report.

04-09-2019 | Systemic lupus erythematosus | Highlight | News

Preliminary trial results support further investigation of low-dose IL-2 therapy for SLE

The low-dose recombinant IL-2 therapy aldesleukin has a favorable safety profile and may restore regulatory T-cell homeostasis in people with systemic lupus erythematosus, suggest findings from a proof-of-concept phase I/IIa clinical trial.

13-08-2019 | Systemic lupus erythematosus | Editorial | Article

Neuropsychiatric systemic lupus erythematosus: Issues in diagnosis and management

Antigone Pieta, Dionysis Nikolopoulos, and Antonis Fanouriakis discuss the causes and management of neuropsychiatric systemic lupus erythematosus, and outline unmet needs in the diagnosis and treatment of this disease.

09-07-2019 | Systemic lupus erythematosus | Highlight | News

Pregnancy outcomes improving for women with SLE

In the past two decades pregnancy outcomes, including in-hospital maternal mortality, have improved among women with systemic lupus erythematosus, but further improvements are needed to reduce risks further, US research shows.

20-06-2019 | Systemic lupus erythematosus | Highlight | Article

Systemic lupus erythematosus: Novel therapies and targeted treatments

Andrea Fava and George Stojan review new strategies and agents for the treatment of systemic lupus erythematosus that have most recently showed promise in clinical trials.

07-05-2019 | Systemic lupus erythematosus | Podcast | Article

A closer look at the EULAR guidelines for managing lupus

Antonis Fanouriakis, lead author of the updated EULAR guidelines for the management of lupus, talks to medwireNews about what’s new in these guidelines and how they will influence clinical practice.

25-02-2019 | Vaccination | Highlight | News

Immunogenicity of influenza vaccine confirmed in patients with rheumatic disease

Influenza vaccination gives rise to an adequate immune response among patients with rheumatic conditions, researchers report.

29-01-2019 | Lupus nephritis | Editorial | Article

Emerging therapies for lupus nephritis

Lupus nephritis is the most common organ-threatening complication of systemic lupus erythematosus, and current treatment regimens are only partially effective and are potentially toxic. In this editorial, the authors focus on emerging therapeutics to treat this disease.

02-01-2019 | Systemic lupus erythematosus | Highlight | News

Add-on omalizumab shows potential for SLE

Preliminary results from a phase Ib trial suggest that add-on treatment with the anti-IgE antibody omalizumab may be a feasible option for patients with systemic lupus erythematosus.

14-12-2018 | Systemic sclerosis | Case study | Article

A systemic sclerosis patient who has undergone autologous stem cell transplantation

Daniel Furst and Nihal Fathi present a case of a patient with diffuse systemic sclerosis who undergoes autologous hematopoietic stem cell transplantation after failing two other therapies.

24-10-2018 | Pediatric | ACR/ARHP 2018 | Video

Expert highlights: Sangeeta Sule

Editorial board member Sangeeta Sule discusses her highlights from the pediatric rheumatology sessions at the 2018 ACR/ARHP Annual Meeting in Chicago, Illinois, USA (2:14).

24-10-2018 | Systemic lupus erythematosus | ACR/ARHP 2018 | Video

Ustekinumab shows potential for the treatment of SLE

Ronald van Vollenhoven discusses phase II trial results demonstrating that the interkeukin-12/23 inhibitor ustekinumab may be a promising treatment option for systemic lupus erythematosus (5:36).

18-10-2018 | Infection | Editorial | Article

Vaccination in children and adolescents with rheumatic conditions

In this editorial, the authors discuss the risks of live vaccination in children taking antirheumatic medications and how to manage these, as well as how health authorities can address decreasing vaccination coverage of the general public.

Image Credits